Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Leerink Partnrs issued their FY2029 EPS estimates for shares of Tourmaline Bio in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($3.15) per share for the year. The consensus estimate for Tourmaline Bio's current full-year earnings is ($2.99) per share.

A number of other brokerages also recently issued reports on TRML. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Guggenheim restated a "buy" rating on shares of Tourmaline Bio in a research report on Wednesday, December 11th. BMO Capital Markets began coverage on shares of Tourmaline Bio in a report on Friday, December 6th. They issued an "outperform" rating and a $50.00 target price on the stock. Finally, HC Wainwright restated a "buy" rating and set a $49.00 price target on shares of Tourmaline Bio in a report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $54.00.

Tourmaline Bio Price Performance

Shares of NASDAQ:TRML traded down $0.95 during midday trading on Friday, hitting $12.98. The company had a trading volume of 221,530 shares, compared to its average volume of 281,815. Tourmaline Bio has a twelve month low of $12.12 and a twelve month high of $48.31. The stock has a market cap of $332.68 million, a price-to-earnings ratio of -4.60 and a beta of 2.32. The business's 50-day simple moving average is $19.77 and its 200-day simple moving average is $21.13.

Institutional Investors Weigh In On Tourmaline Bio

A number of institutional investors have recently made changes to their positions in TRML. Rhumbline Advisers grew its position in Tourmaline Bio by 2.1% in the 4th quarter. Rhumbline Advisers now owns 35,591 shares of the company's stock valued at $722,000 after acquiring an additional 718 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Tourmaline Bio by 3.4% in the fourth quarter. SG Americas Securities LLC now owns 34,812 shares of the company's stock worth $706,000 after acquiring an additional 1,140 shares in the last quarter. Brooklyn Investment Group acquired a new stake in shares of Tourmaline Bio in the fourth quarter valued at $32,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Tourmaline Bio by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company's stock valued at $127,000 after acquiring an additional 1,920 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Tourmaline Bio by 16.5% in the third quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company's stock valued at $381,000 after purchasing an additional 2,100 shares during the period. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.